Please enable JavaScript to continue using this application.

Compare $OCGN vs $PRLD | Chartloom

Compare

$OCGN vs $PRLD

Ocugen Inc · Prelude Therapeutics Inc

OCGN

Ocugen Inc

PRLD

Prelude Therapeutics Inc

Compare $OCGN vs $PRLD

Comparing Ocugen Inc and Prelude Therapeutics Inc

OCGNOcugen Inc

PRLDPrelude Therapeutics Inc

OCGNOcugen Inc

Market cap

$323M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

181.62x

Rev growth (TTM)

0.4%

YTD performance

-30.8%

52W performance

-46.6%

FCF yield

-18.9%

PRLDPrelude Therapeutics Inc

Market cap

$310M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.94x

Rev growth (TTM)

—

YTD performance

42.5%

52W performance

173.9%

FCF yield

-10.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

OCGN

PRLD

Detailed metrics comparison

OCGN

Ocugen Inc

PRLD

Prelude Therapeutics Inc

Market Cap

OCGN$323M

PRLD$310M

Enterprise Value

OCGN$308M

PRLD$284M

Price

OCGN$0.96

PRLD$3.89

P/E Ratio

OCGNN/A

PRLDN/A

P/S Ratio

OCGN67.77x

PRLD13.82x

EV/Sales

OCGN64.43x

PRLD12.64x

EV/EBITDA

OCGN0.00x

PRLD0.00x

P/B Ratio

OCGN59.59x

PRLD2.19x

P/FCF Ratio

OCGNN/A

PRLDN/A

EV/FCF

OCGN-5.04x

PRLD-8.53x

PEG Ratio

OCGNN/A

PRLDN/A

Forward P/E (NTM)

OCGNN/A

PRLDN/A

Forward P/S (NTM)

OCGN181.62x

PRLD5.94x

Revenue (TTM)

OCGN$5M

PRLD$22M

Revenue Growth (YoY)

OCGN0.4%

PRLDN/A

Forward Rev Growth

OCGN-47.4%

PRLD-14.3%

Gross Margin (TTM)

OCGN0.0%

PRLD0.0%

Operating Margin (TTM)

OCGN0.0%

PRLD0.0%

EBITDA Margin (TTM)

OCGN-1043.0%

PRLD-293.5%

Net Margin (TTM)

OCGN-1343.1%

PRLD-269.7%

FCF Margin (TTM)

OCGN-1278.5%

PRLD-148.3%

Net Income (TTM)

OCGN$-64M

PRLD$-60M

FCF (TTM)

OCGN$-61M

PRLD$-33M

EPS (TTM)

OCGN-$0.19

PRLD-$0.61

ROE (TTM)

OCGN-130671.0%

PRLD-7535.0%

ROA (TTM)

OCGN-8057.0%

PRLD-4439.0%

ROIC (TTM)

OCGN-16519.0%

PRLD-7535.0%

Cash

OCGN$100M

PRLD$26M

Debt

OCGN$84M

PRLD$0

Net Cash/Debt

OCGN$16M

PRLD$26M

Current Ratio (TTM)

OCGN0.80x

PRLD4.07x

Quick Ratio (TTM)

OCGN0.75x

PRLD3.99x

Debt/Equity (TTM)

OCGN5.03x

PRLD0.00x

Debt/Assets (TTM)

OCGN0.0%

PRLD0.0%

Interest Coverage (TTM)

OCGNN/A

PRLDN/A

Net Debt/EBITDA (TTM)

OCGN0.00x

PRLD0.00x

Beta

OCGN1.91

PRLD1.19

52W Performance

OCGN-46.6%

PRLD173.9%

YTD Performance

OCGN-30.8%

PRLD42.5%

% from 52W High

OCGN-64.9%

PRLD-43.0%

% from 52W Low

OCGN6.2%

PRLD238.3%

Asset Turnover (TTM)

OCGN0.06x

PRLD0.16x

FCF Yield (TTM)

OCGN-18.9%

PRLD-10.7%

Earnings Yield (TTM)

OCGN-19.8%

PRLD-19.5%

Dividend Yield (TTM)

OCGNN/A

PRLDN/A

Rule of 40

OCGN-1,278.1

PRLD-148.3

EV/GP/RG

OCGNN/A

PRLDN/A

Ticker research

View OCGN research View PRLD research

Metric	OCGN Ocugen Inc	PRLD Prelude Therapeutics Inc
Market & Valuation
Market Cap	$323M	$310M
Enterprise Value	$308M	$284M
Price	$0.96	$3.89
P/E Ratio	N/A	N/A
P/S Ratio	67.77x	13.82x
EV/Sales	64.43x	12.64x
EV/EBITDA	0.00x	0.00x
P/B Ratio	59.59x	2.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.04x	-8.53x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	181.62x	5.94x
Revenue & Growth
Revenue (TTM)	$5M	$22M
Revenue Growth (YoY)	0.4%	N/A
Forward Rev Growth	-47.4%	-14.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1043.0%	-293.5%
Net Margin (TTM)	-1343.1%	-269.7%
FCF Margin (TTM)	-1278.5%	-148.3%
Net Income (TTM)	$-64M	$-60M
FCF (TTM)	$-61M	$-33M
EPS (TTM)	-$0.19	-$0.61
ROE (TTM)	-130671.0%	-7535.0%
ROA (TTM)	-8057.0%	-4439.0%
ROIC (TTM)	-16519.0%	-7535.0%
Financial Health
Cash	$100M	$26M
Debt	$84M	$0
Net Cash/Debt	$16M	$26M
Current Ratio (TTM)	0.80x	4.07x
Quick Ratio (TTM)	0.75x	3.99x
Debt/Equity (TTM)	5.03x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.91	1.19
52W Performance	-46.6%	173.9%
YTD Performance	-30.8%	42.5%
% from 52W High	-64.9%	-43.0%
% from 52W Low	6.2%	238.3%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.16x
FCF Yield (TTM)	-18.9%	-10.7%
Earnings Yield (TTM)	-19.8%	-19.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,278.1	-148.3
EV/GP/RG	N/A	N/A
Ticker research	View OCGN research	View PRLD research

Valuation

P/S Ratio

PRLD

13.82x

OCGN

67.77x

EV/FCF

PRLD

-8.53x

OCGN

-5.04x

Growth & revenue

Revenue Growth TTM

OCGN

0.4%

Forward Revenue Growth

PRLD

-14.3%

OCGN

-47.4%

Profitability & performance

Gross Margin

OCGN

0.0%

PRLD

0.0%

ROE

PRLD

-7535.0%

OCGN

-130671.0%

FCF Yield %

PRLD

-10.7%

OCGN

-18.9%

52-Week Performance

PRLD

173.9%

OCGN

-46.6%

Detailed metrics comparison

OCGN

Ocugen Inc

PRLD

Prelude Therapeutics Inc

Market Cap

OCGN$323M

PRLD$310M

Enterprise Value

OCGN$308M

PRLD$284M

Price

OCGN$0.96

PRLD$3.89

P/E Ratio

OCGNN/A

PRLDN/A

P/S Ratio

OCGN67.77x

PRLD13.82x

EV/Sales

OCGN64.43x

PRLD12.64x

EV/EBITDA

OCGN0.00x

PRLD0.00x

P/B Ratio

OCGN59.59x

PRLD2.19x

P/FCF Ratio

OCGNN/A

PRLDN/A

EV/FCF

OCGN-5.04x

PRLD-8.53x

PEG Ratio

OCGNN/A

PRLDN/A

Forward P/E (NTM)

OCGNN/A

PRLDN/A

Forward P/S (NTM)

OCGN181.62x

PRLD5.94x

Revenue (TTM)

OCGN$5M

PRLD$22M

Revenue Growth (YoY)

OCGN0.4%

PRLDN/A

Forward Rev Growth

OCGN-47.4%

PRLD-14.3%

Gross Margin (TTM)

OCGN0.0%

PRLD0.0%

Operating Margin (TTM)

OCGN0.0%

PRLD0.0%

EBITDA Margin (TTM)

OCGN-1043.0%

PRLD-293.5%

Net Margin (TTM)

OCGN-1343.1%

PRLD-269.7%

FCF Margin (TTM)

OCGN-1278.5%

PRLD-148.3%

Net Income (TTM)

OCGN$-64M

PRLD$-60M

FCF (TTM)

OCGN$-61M

PRLD$-33M

EPS (TTM)

OCGN-$0.19

PRLD-$0.61

ROE (TTM)

OCGN-130671.0%

PRLD-7535.0%

ROA (TTM)

OCGN-8057.0%

PRLD-4439.0%

ROIC (TTM)

OCGN-16519.0%

PRLD-7535.0%

Cash

OCGN$100M

PRLD$26M

Debt

OCGN$84M

PRLD$0

Net Cash/Debt

OCGN$16M

PRLD$26M

Current Ratio (TTM)

OCGN0.80x

PRLD4.07x

Quick Ratio (TTM)

OCGN0.75x

PRLD3.99x

Debt/Equity (TTM)

OCGN5.03x

PRLD0.00x

Debt/Assets (TTM)

OCGN0.0%

PRLD0.0%

Interest Coverage (TTM)

OCGNN/A

PRLDN/A

Net Debt/EBITDA (TTM)

OCGN0.00x

PRLD0.00x

Beta

OCGN1.91

PRLD1.19

52W Performance

OCGN-46.6%

PRLD173.9%

YTD Performance

OCGN-30.8%

PRLD42.5%

% from 52W High

OCGN-64.9%

PRLD-43.0%

% from 52W Low

OCGN6.2%

PRLD238.3%

Asset Turnover (TTM)

OCGN0.06x

PRLD0.16x

FCF Yield (TTM)

OCGN-18.9%

PRLD-10.7%

Earnings Yield (TTM)

OCGN-19.8%

PRLD-19.5%

Dividend Yield (TTM)

OCGNN/A

PRLDN/A

Rule of 40

OCGN-1,278.1

PRLD-148.3

EV/GP/RG

OCGNN/A

PRLDN/A

Ticker research

View OCGN research View PRLD research

Metric	OCGN Ocugen Inc	PRLD Prelude Therapeutics Inc
Market & Valuation
Market Cap	$323M	$310M
Enterprise Value	$308M	$284M
Price	$0.96	$3.89
P/E Ratio	N/A	N/A
P/S Ratio	67.77x	13.82x
EV/Sales	64.43x	12.64x
EV/EBITDA	0.00x	0.00x
P/B Ratio	59.59x	2.19x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.04x	-8.53x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	181.62x	5.94x
Revenue & Growth
Revenue (TTM)	$5M	$22M
Revenue Growth (YoY)	0.4%	N/A
Forward Rev Growth	-47.4%	-14.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1043.0%	-293.5%
Net Margin (TTM)	-1343.1%	-269.7%
FCF Margin (TTM)	-1278.5%	-148.3%
Net Income (TTM)	$-64M	$-60M
FCF (TTM)	$-61M	$-33M
EPS (TTM)	-$0.19	-$0.61
ROE (TTM)	-130671.0%	-7535.0%
ROA (TTM)	-8057.0%	-4439.0%
ROIC (TTM)	-16519.0%	-7535.0%
Financial Health
Cash	$100M	$26M
Debt	$84M	$0
Net Cash/Debt	$16M	$26M
Current Ratio (TTM)	0.80x	4.07x
Quick Ratio (TTM)	0.75x	3.99x
Debt/Equity (TTM)	5.03x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.91	1.19
52W Performance	-46.6%	173.9%
YTD Performance	-30.8%	42.5%
% from 52W High	-64.9%	-43.0%
% from 52W Low	6.2%	238.3%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.16x
FCF Yield (TTM)	-18.9%	-10.7%
Earnings Yield (TTM)	-19.8%	-19.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,278.1	-148.3
EV/GP/RG	N/A	N/A
Ticker research	View OCGN research	View PRLD research